Dosage and administration
Adults & Children ages 6 - 12: 4 tablets. Children ages 2 - 6: 2 tablets. Dissolve under tongue 3 times a day. Use more frequently (every 15 minutes for up to 8 doses) with acute conditions.
Adults & Children ages 6 - 12: 4 tablets. Children ages 2 - 6: 2 tablets. Dissolve under tongue 3 times a day. Use more frequently (every 15 minutes for up to 8 doses) with acute conditions.
Adults & Children ages 6 - 12: 4 tablets. Children ages 2 - 6: 2 tablets. Dissolve under tongue 3 times a day.
Use more frequently (every 15 minutes for up to 8 doses) with acute conditions.
Relief of symptoms of colds with yellow discharge and post nasal drip. Relief of symptoms of sore throat. Relief of symptoms of pimples and blemishes associated with common acne.
Calcarea Sulphurica 30X HPUS in a base of Acacia Gum, Lactose N.F.
Do not use if imprinted cap band is broken or missing. If symptoms persist for more than seven days or worsen, contact a licensed health care provider.
Discontinue use if symptoms are accompanied by a high fever (over 101° F). Severe or persistent sore throat accompanied by high fever, headache, nausea, and vomiting may be serious. Consult physician promptly.
Do not use more than 2 days or administer to children under 3 years of age unless directed by physician.
If you are pregnant or nursing, seek the advice of a licensed health care provider before using this product.
Keep this and all medications out of the reach of children.
800.624.9659
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CALCIUM SULFATE | ACTIVE INGREDIENT | WAT0DDB505 | 1 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 1 | |
| Acacia | INACTIVE INGREDIENT | 5C5403N26O | 1 | |
| Lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54973-3103 | 54973-3103-1, 54973-3103-2 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LACTOSE | J2B2A4N98G | IACT |
| ACACIA | 5C5403N26O | IACT |
| CALCIUM SULFATE | WAT0DDB505 | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| Acacia | ACACIA | 5C5403N26O | GUM, CHEWING / BUCCAL | 280 mg | ||
| Acacia | ACACIA | 5C5403N26O | TABLET, FILM COATED / ORAL | 0.14 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| Acacia | ACACIA | 5C5403N26O | TABLET / SUBLINGUAL | 9.1 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| Acacia | ACACIA | 5C5403N26O | SUSPENSION / ORAL | 2 mg | ||
| Acacia | ACACIA | 5C5403N26O | POWDER, FOR SUSPENSION / ORAL | 7386 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| Lactose | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| Lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| Acacia | ACACIA | 5C5403N26O | TABLET, DELAYED RELEASE / ORAL | 30 mg | ||
| Acacia | ACACIA | 5C5403N26O | TABLET, CHEWABLE / ORAL | 121 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| Acacia | ACACIA | 5C5403N26O | SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| Acacia | ACACIA | 5C5403N26O | TABLET, ORALLY DISINTEGRATING / ORAL | 7 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| Acacia | ACACIA | 5C5403N26O | POWDER / ORAL | 800 mg | ||
| Acacia | ACACIA | 5C5403N26O | TABLET, EXTENDED RELEASE / ORAL | 34.4 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| Acacia | ACACIA | 5C5403N26O | SYRUP / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| Acacia | ACACIA | 5C5403N26O | TABLET / ORAL | 70 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| Acacia | ACACIA | 5C5403N26O | CAPSULE, EXTENDED RELEASE / ORAL | 64 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| Acacia | ACACIA | 5C5403N26O | CAPSULE / ORAL | 20 mg | ||
| Acacia | ACACIA | 5C5403N26O | LOZENGE / ORAL | 108 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| Acacia | ACACIA | 5C5403N26O | TABLET, COATED / ORAL | 156 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| Acacia | ACACIA | 5C5403N26O | TABLET / BUCCAL | 9.1 mg | ||
| Acacia | ACACIA | 5C5403N26O | POWDER, FOR SOLUTION / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d436d094-a364-6150-e053-2995a90a1ce4 | cba3ecf3-2954-4793-8563-dfc6a2c80150 | 2021-12-28 | Warnings | cba3ecf3-2954-4793-8563-dfc6a2c80150 |
Adverse event summaries are temporarily unavailable. Other product information remains available.